Allergy & Anaphylaxis Australia (A&AA) is pleased to  announce the Therapeutic Goods Administration (TGA) is currently reviewing two  applications for registration of alternate adrenaline injectors in the Australian market. It is important that people at risk of anaphylaxis and their treating doctor can discuss options of adrenaline injector devices and choose a device that best suits their needs.

SYMJEPI®, an adrenaline injector which is a pre filled syringe in protective casing that fits in the palm of your hand was on the Pharmaceutical Benefits Advisory Committee (PBAC) agenda of the July 2020 meeting. We are waiting to hear on progression of registration and Pharmaceutical Benefits Scheme (PBS) listing. A&AA is in communication with the Australian sponsor of the device. (SYMJEPI® comes in 150mcg and 300mcg doses). Information on SYMJEPI® can be found at www.symjepi.com

Graphic of SYMJEPI has been taken from the American website above. 

 

ANAPEN®, a revised adrenaline autoinjector which comes with an added 500mcg dose for people 50kg and over(as per ASCIA prescription guidelines) is tabled on the agenda of the November 2020 PBAC meeting. Anapen® also comes in 150mcg and 300mcg doses. A&AA is in communication with the Australian sponsor of the device. People wanting to write a submission expressing their thoughts on registration and PBS listing of Anapen® can click on this link. Note that submissions close on the 7 October 2020.

More information on Anapen® can be found at www.bioprojet.com/en/products/anapen

New design Anapen®

A&AA will continue to advocate for Auvi-Q®, a Kaleo product, to be an option for Australians living with the risk of anaphylaxis.